Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Ann Emerg Med ; 77(1): 19-31, 2021 01.
Article in English | MEDLINE | ID: covidwho-1382201

ABSTRACT

STUDY OBJECTIVE: To synthesize the evidence regarding the infection risk associated with different modalities of oxygen therapy used in treating patients with severe acute respiratory infection. Health care workers face significant risk of infection when treating patients with a viral severe acute respiratory infection. To ensure health care worker safety and limit nosocomial transmission of such infection, it is crucial to synthesize the evidence regarding the infection risk associated with different modalities of oxygen therapy used in treating patients with severe acute respiratory infection. METHODS: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched from January 1, 2000, to April 1, 2020, for studies describing the risk of infection associated with the modalities of oxygen therapy used for patients with severe acute respiratory infection. The study selection, data extraction, and quality assessment were performed by independent reviewers. The primary outcome measure was the infection of health care workers with a severe acute respiratory infection. Random-effect models were used to synthesize the extracted data. RESULTS: Of 22,123 citations, 50 studies were eligible for qualitative synthesis and 16 for meta-analysis. Globally, the quality of the included studies provided a very low certainty of evidence. Being exposed or performing an intubation (odds ratio 6.48; 95% confidence interval 2.90 to 14.44), bag-valve-mask ventilation (odds ratio 2.70; 95% confidence interval 1.31 to 5.36), and noninvasive ventilation (odds ratio 3.96; 95% confidence interval 2.12 to 7.40) were associated with an increased risk of infection. All modalities of oxygen therapy generate air dispersion. CONCLUSION: Most modalities of oxygen therapy are associated with an increased risk of infection and none have been demonstrated as safe. The lowest flow of oxygen should be used to maintain an adequate oxygen saturation for patients with severe acute respiratory infection, and manipulation of oxygen delivery equipment should be minimized.


Subject(s)
Cross Infection/transmission , Infectious Disease Transmission, Patient-to-Professional , Oxygen Inhalation Therapy , Severe Acute Respiratory Syndrome/transmission , Cross Infection/therapy , Humans , Oxygen Inhalation Therapy/adverse effects , Risk Factors , Severe Acute Respiratory Syndrome/therapy
2.
Infect Control Hosp Epidemiol ; 42(6): 746-750, 2021 06.
Article in English | MEDLINE | ID: covidwho-1263424

ABSTRACT

A questionnaire was distributed to hospitals in Tokyo (N = 38) regarding their preparedness against and in-facility transmission of coronavirus disease 2019 (COVID-19). As of May 31, 2020, 284 HCP had contracted COVID-19, and in-facility COVID-19 transmission occurred at 13 hospitals, negatively impacting hospital functions and patient care.


Subject(s)
COVID-19/epidemiology , Cross Infection/epidemiology , Personnel, Hospital/psychology , Adult , Aged , Aged, 80 and over , COVID-19/prevention & control , COVID-19/therapy , COVID-19/transmission , Cross Infection/prevention & control , Cross Infection/therapy , Cross Infection/transmission , Female , Humans , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Infectious Disease Transmission, Patient-to-Professional/statistics & numerical data , Male , Middle Aged , Personnel, Hospital/statistics & numerical data , Surveys and Questionnaires , Tokyo/epidemiology , Young Adult
4.
Clin Exp Nephrol ; 25(6): 652-659, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1068749

ABSTRACT

BACKGROUND: Blood purification therapy is a treatment method, wherein many patients gather in the same space to receive regular treatments, possibly increasing the risk of contracting the coronavirus disease 2019 (COVID-19) through contact, droplet, and aerosol. We experienced a nosocomial outbreak and evaluated the clinical characteristics of COVID-19 infection in patients undergoing blood purification therapy. METHODS: We retrospectively analyzed 28 patients who underwent blood purification therapy at the dialysis center of our hospital from April 2, 2020, to April 29, 2020. Logistic regression analysis was performed to identify clinical factors related to COVID-19 for 18 patients who were tested using real-time reverse transcriptase-polymerase chain reaction (RT-PCR). RESULTS: Of the 28 patients, seven were COVID-19 positive, as confirmed by RT-PCR. The median age was 77 years, 22 patients were male (79%), four patients had acute kidney injury (14%), and six patients were bedridden (21%). All infected patients had been admitted to the wards where the nosocomial outbreak had occurred. Logistic regression analysis revealed that being bedridden (odds ratio 13.33, 95% confidence interval 1.05-169.56, p < 0.05) was significantly related to COVID-19 infection. However, the Charlson comorbidity index, receiving dialysis in the same room, and adjacency of the dialysis bed to COVID-19-positive patients before the confirmation of infection did not reveal any significant relationship. CONCLUSION: Bedridden patients admitted to nosocomial infection wards were associated with COVID-19 infection, and transmission within the dialysis center was not observed. More rigorous infection control measures need to be implemented for bedridden patients undergoing blood purification therapy.


Subject(s)
COVID-19/therapy , COVID-19/transmission , Cross Infection/therapy , Cross Infection/transmission , Hemodialysis Units, Hospital , Acute Kidney Injury/complications , Adult , Aged , Aged, 80 and over , Cohort Studies , Comorbidity , Disease Outbreaks , Female , Hospitalization , Humans , Infection Control , Male , Middle Aged , Polymerase Chain Reaction , Renal Dialysis , Retrospective Studies
5.
Encephale ; 46(3S): S99-S106, 2020 Jun.
Article in French | MEDLINE | ID: covidwho-1065056

ABSTRACT

COVID-19 is a multi-organ disease due to an infection with the SARS-CoV2 virus. It has become a pandemic in early 2020. The disease appears less devastating in children and adolescents. However, stress, quarantine and eventually mourning have major impacts on development. It is difficult to describe what this pandemic implies for a child psychiatrist, other than by giving a first-hand account. I propose to go through the main ethical questions that have arisen; to describe how my hospital team has reorganized itself to meet the new demands and questions, in particular by opening a unit dedicated to people with autism and challenging behaviors affected by COVID-19; and to address, in a context of national discussion, how the discipline has sought to understand the conditions of a certain well-being during quarantine. Finally, I will try to conclude with more speculative reflections on re-opening.


Subject(s)
Adolescent Psychiatry , Attitude of Health Personnel , Autistic Disorder/therapy , Betacoronavirus , Child Psychiatry , Coronavirus Infections , Pandemics , Pneumonia, Viral , Psychiatry , Adolescent , Adolescent Behavior , Adolescent Psychiatry/ethics , Autistic Disorder/complications , Autistic Disorder/psychology , COVID-19 , Child , Child Behavior , Child Psychiatry/ethics , Communicable Disease Control/methods , Coronavirus Infections/complications , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Coronavirus Infections/psychology , Coronavirus Infections/transmission , Cross Infection/complications , Cross Infection/psychology , Cross Infection/therapy , Environmental Exposure , France , Health Services Accessibility , Hospital Restructuring , Hospital Units/organization & administration , Humans , Infection Control/methods , Mental Health Services/ethics , Mental Health Services/organization & administration , Olfaction Disorders/etiology , Olfaction Disorders/psychology , Pandemics/prevention & control , Patient Acceptance of Health Care , Patient Care Team , Patient Isolation/psychology , Play Therapy , Pneumonia, Viral/complications , Pneumonia, Viral/prevention & control , Pneumonia, Viral/psychology , Pneumonia, Viral/transmission , Professional Practice/ethics , Protective Devices , Risk Factors , SARS-CoV-2 , Stress, Psychological/etiology
7.
S Afr Fam Pract (2004) ; 62(1): e1-e6, 2020 11 16.
Article in English | MEDLINE | ID: covidwho-951602

ABSTRACT

The ongoing coronavirus disease 2019 (COVID-19) pandemic presented a huge challenge to the health systems across the world. When the virus hit South Africa, and the state of national disaster was announced by the president, the healthcare system had to work on its COVID-19 response preparedness. Initially, a few hospitals were then designated facilities for managing COVID-19 patients. Kalafong Hospital, which was not amongst a list of designated facilities for COVID-19 was forced to evaluate its level of preparedness after an intern doctor tested positive. The objectives of this report are to illustrate the hospital's response around the management of the index case to share our facility's general response to the pandemic.


Subject(s)
COVID-19/transmission , Cross Infection/prevention & control , Infection Control/organization & administration , Infectious Disease Transmission, Professional-to-Patient/prevention & control , Tertiary Care Centers/organization & administration , COVID-19/diagnosis , COVID-19/prevention & control , COVID-19/therapy , COVID-19 Testing , Cross Infection/diagnosis , Cross Infection/therapy , Humans , Internship and Residency , Pandemics , SARS-CoV-2 , South Africa/epidemiology
8.
Cleve Clin J Med ; 87(11): 659-663, 2020 11 02.
Article in English | MEDLINE | ID: covidwho-908366

ABSTRACT

In COVID-19, respiratory infection with SARS-CoV-2 plus another virus (viral co-infection) or with SARS-CoV-2 plus a bacterial pathogen (combined viral and bacterial pneumonia) has been described. Secondary bacterial pneumonia can follow the initial phase of viral respiratory infection or occur during the recovery phase. No obvious pattern or guidelines exist for viral co-infection, combined viral and bacterial pneumonia, or secondary bacterial pneumonia in COVID-19. Based on existing clinical data and experience with similar viruses such as influenza and SARS-CoV, the management approach in COVID-19 should, ideally, take into consideration the overall presentation and the trajectory of illness.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Coinfection , Coronavirus Infections , Pandemics , Patient Care Management/methods , Pneumonia, Bacterial , Pneumonia, Viral , Virus Diseases , Bacteria/classification , Bacteria/isolation & purification , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques/methods , Coinfection/diagnosis , Coinfection/etiology , Coinfection/therapy , Community-Acquired Infections/epidemiology , Community-Acquired Infections/therapy , Coronavirus Infections/diagnosis , Coronavirus Infections/epidemiology , Coronavirus Infections/therapy , Cross Infection/epidemiology , Cross Infection/therapy , Diagnosis, Differential , Humans , Pneumonia, Bacterial/epidemiology , Pneumonia, Bacterial/etiology , Pneumonia, Bacterial/therapy , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , Pneumonia, Viral/therapy , Virus Diseases/epidemiology , Virus Diseases/therapy
9.
Am J Emerg Med ; 45: 483-489, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-807767

ABSTRACT

OBJECTIVE: There are growing concerns regarding the lack of COVID-19 pandemic response capacity in already overwhelmed emergency departments (EDs), and lack of proper isolation facilities. This study evaluated the effectiveness of the negative pressure isolation stretcher (NPIS) and additional negative pressure isolation rooms (NPIRs) on the maintenance of emergency care capacity during the COVID-19 outbreak. METHODS: A before and after intervention study was performed between February 27, 2020 and March 31, 2020 at the ED of Chungbuk National University Hospital, Cheongju, South Korea. A total of 2455 patients who visited the ED during the study period were included. Interventions included the introduction of the NPIS and additional NPIRs in the ED. The main outcome of the study was frequency of medical cessation. Secondary outcomes were the average number of ED visits and lengths of stay. RESULTS: After the intervention, average frequency of medical cessation was significantly decreased from 1.6 times per day (range 0-4) in the pre-intervention period to 0.6 times per day (range 0-3) in the post-intervention period (p-value <0.01). On the other hand, the number of patients visiting the ED increased significantly from 67.2 persons per day (range 58-79) pre-intervention to 76.3 persons per day (range 61-88) post-intervention (p value <0.01). However, there were no statistically significant differences in the average ED length of stay across the study phases (p value = 0.50). CONCLUSIONS: This intervention may provide an effective way to prepare and meet the ED response needs of the COVID-19 pandemic.


Subject(s)
COVID-19/therapy , Cross Infection/therapy , Emergency Medical Services/methods , Pandemics , Patient Isolation/instrumentation , SARS-CoV-2 , Adult , Aged , Communicable Disease Control , Comorbidity , Cross Infection/epidemiology , Emergency Service, Hospital , Equipment Design , Female , Humans , Male , Middle Aged , Republic of Korea/epidemiology , Retrospective Studies
10.
Am J Case Rep ; 21: e927452, 2020 Sep 25.
Article in English | MEDLINE | ID: covidwho-796272

ABSTRACT

BACKGROUND COVID-19 is an infectious disease caused by SARS-CoV-2. It has spread rapidly through the world, endangering human life. The main target of COVID-19 is the lungs; however, it can involve other organs, including the liver. Patients with severe COVID-19 have an increased incidence of abnormal liver function, and patients with liver disorders are considered to be at a higher risk of severe COVID-19 infection. The mechanism of liver injury reported in 14% to 53% of COVID-19 patients is poorly recognized and several possibilities need to be considered (cytokine storm, direct viral action, hypoxia). The incidence of underlying liver comorbidities in patients with a COVID-19 infection ranges from 1% to 11%. CASE REPORT This is a report of 2 nosocomial COVID-19 infections and severe COVID-19 pneumonia in 2 patients who were hospitalized during treatment for alcoholic liver disease (ALD). Case 1 and case 2 were a 31-year-old woman and a 40-year-old woman, respectively, with decompensated ALD and symptoms of the COVID-19 infection. Both patients were transferred from another hospital to our hospital after confirmation of COVID-19 during their hospitalization. The course of the infection progressed rapidly in both patients with the development of multiple-organ failure and death over a short period. CONCLUSIONS There are no clear recommendations on the management of ALD in the COVID-19 pandemic. Alcoholic hepatitis may be a risk factor for severe COVID-19 and a poor outcome. A high percentage of nosocomial COVID-19 infections are observed; therefore, special precautions should be taken to minimize the risk of COVID-19 exposure.


Subject(s)
Coronavirus Infections/diagnosis , Cross Infection/diagnosis , Liver Diseases, Alcoholic/therapy , Pneumonia, Viral/diagnosis , Severe Acute Respiratory Syndrome/diagnostic imaging , Tomography, X-Ray Computed/methods , Adult , COVID-19 , Combined Modality Therapy , Coronavirus Infections/complications , Cross Infection/therapy , Disease Progression , Fatal Outcome , Female , Hospitalization , Humans , Liver Diseases, Alcoholic/diagnosis , Multiple Organ Failure , Pandemics , Pneumonia, Viral/complications , Radiography, Thoracic/methods , Respiration, Artificial , Risk Assessment
11.
Acta Biomed ; 91(9-S): 90-91, 2020 07 20.
Article in English | MEDLINE | ID: covidwho-669802

ABSTRACT

The short paper present the problem of hospital acquired infection in subintensive units og a research and teaching hospital.


Subject(s)
Betacoronavirus , Coronavirus Infections/therapy , Cross Infection/therapy , Pneumonia, Viral/therapy , COVID-19 , Coronavirus Infections/prevention & control , Hospitals, Teaching , Humans , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , SARS-CoV-2
12.
Clin Microbiol Infect ; 27(1): 83-88, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-764421

ABSTRACT

OBJECTIVES: To describe the burden, epidemiology and outcomes of co-infections and superinfections occurring in hospitalized patients with coronavirus disease 2019 (COVID-19). METHODS: We performed an observational cohort study of all consecutive patients admitted for ≥48 hours to the Hospital Clinic of Barcelona for COVID-19 (28 February to 22 April 2020) who were discharged or dead. We describe demographic, epidemiologic, laboratory and microbiologic results, as well as outcome data retrieved from electronic health records. RESULTS: Of a total of 989 consecutive patients with COVID-19, 72 (7.2%) had 88 other microbiologically confirmed infections: 74 were bacterial, seven fungal and seven viral. Community-acquired co-infection at COVID-19 diagnosis was uncommon (31/989, 3.1%) and mainly caused by Streptococcus pneumoniae and Staphylococcus aureus. A total of 51 hospital-acquired bacterial superinfections, mostly caused by Pseudomonas aeruginosa and Escherichia coli, were diagnosed in 43 patients (4.7%), with a mean (SD) time from hospital admission to superinfection diagnosis of 10.6 (6.6) days. Overall mortality was 9.8% (97/989). Patients with community-acquired co-infections and hospital-acquired superinfections had worse outcomes. CONCLUSIONS: Co-infection at COVID-19 diagnosis is uncommon. Few patients developed superinfections during hospitalization. These findings are different compared to those of other viral pandemics. As it relates to hospitalized patients with COVID-19, such findings could prove essential in defining the role of empiric antimicrobial therapy or stewardship strategies.


Subject(s)
Bacterial Infections/epidemiology , COVID-19/epidemiology , Cross Infection/epidemiology , Mycoses/epidemiology , SARS-CoV-2/pathogenicity , Superinfection/epidemiology , Virus Diseases/epidemiology , Aged , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/microbiology , Bacterial Infections/mortality , Bacterial Infections/therapy , Bacterial Typing Techniques , Blood Culture/methods , COVID-19/mortality , COVID-19/therapy , COVID-19/virology , Coinfection , Community-Acquired Infections , Cross Infection/microbiology , Cross Infection/mortality , Cross Infection/therapy , Female , Hospitalization , Hospitals , Humans , Incidence , Male , Middle Aged , Mycoses/microbiology , Mycoses/mortality , Mycoses/therapy , Retrospective Studies , Spain/epidemiology , Sputum/microbiology , Superinfection/mortality , Superinfection/therapy , Superinfection/virology , Survival Analysis , Virus Diseases/mortality , Virus Diseases/therapy , Virus Diseases/virology
13.
Transpl Infect Dis ; 22(6): e13364, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-592352

ABSTRACT

Solid organ transplant recipients are considered at high risk for COVID-19 infection due to chronic immune suppression; little data currently exists on the manifestations and outcomes of COVID-19 infection in lung transplant recipients. Here we report 8 cases of COVID-19 identified in patients with a history of lung transplant. We describe the clinical course of disease as well as preexisting characteristics of these patients.


Subject(s)
COVID-19/physiopathology , Cross Infection/physiopathology , Immunosuppressive Agents/therapeutic use , Lung Transplantation , Adenosine Monophosphate/analogs & derivatives , Adenosine Monophosphate/therapeutic use , Adult , Aged , Alanine/analogs & derivatives , Alanine/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Antiviral Agents/therapeutic use , COVID-19/diagnostic imaging , COVID-19/immunology , COVID-19/therapy , Cough/physiopathology , Cross Infection/diagnostic imaging , Cross Infection/immunology , Cross Infection/therapy , Cystic Fibrosis/surgery , Dyspnea/physiopathology , Female , Fever/physiopathology , Gastrointestinal Diseases/physiopathology , Glucocorticoids/therapeutic use , Graft Rejection/prevention & control , Humans , Idiopathic Pulmonary Fibrosis/surgery , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Lung/diagnostic imaging , Male , Methylprednisolone/therapeutic use , Middle Aged , Pancreatitis, Acute Necrotizing , Pulmonary Disease, Chronic Obstructive/surgery , Pulse Therapy, Drug , SARS-CoV-2 , Sepsis , Severity of Illness Index , Tomography, X-Ray Computed
14.
Ann Thorac Surg ; 110(6): e461-e463, 2020 12.
Article in English | MEDLINE | ID: covidwho-549140

ABSTRACT

The novel coronavirus disease 2019 is a highly contagious viral infection caused by the severe acute respiratory syndrome coronavirus 2 virus. Its rapid spread and severe clinical presentation influence patient management in all specialties including thoracic surgery. We report 3 cases of coronavirus disease 2019 occurring in patients shortly after thoracotomy and thoracoscopy procedures, illustrating the imminent threat of severe acute respiratory syndrome coronavirus 2 infection for thoracic surgery patients.


Subject(s)
Betacoronavirus , Coronavirus Infections/diagnosis , Cross Infection/diagnosis , Lung Neoplasms/surgery , Pneumonectomy/adverse effects , Pneumonia, Viral/diagnosis , Postoperative Complications/diagnosis , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Aged , COVID-19 , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Coronavirus Infections/etiology , Coronavirus Infections/therapy , Cross Infection/etiology , Cross Infection/therapy , Female , Humans , Lung Neoplasms/pathology , Male , Middle Aged , Pandemics , Pneumonia, Viral/etiology , Pneumonia, Viral/therapy , Postoperative Complications/etiology , Postoperative Complications/therapy , SARS-CoV-2 , Thoracoscopy/adverse effects , Thoracotomy/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL